Global Viral Vector and Plasmid DNA Manufacturing Market, 7th Edition: Forecast to 2035 | 9.73% CAGR Unlocks USD 2.16 Billion CMO and Gene Therapy Opportunity

Boost ROI through strategic CMO alliances, high-density cell culture and automation to improve scalability, vector yields, workflow efficiency and market positioning.Dublin, Oct. 20, 2026 (GLOBE ...
Yahoo Finance

Viral Vector and Plasmid DNA Manufacturing Market Report 2026: 130+ Players Drive Shift Toward Integrated Commercial-Scale Manufacturing - Industry Trends and Global Forecasts ...

Dublin, April 20, 2026 (GLOBE NEWSWIRE)-- The "Viral Vector and Plasmid DNA Manufacturing Market (7th Edition): Industry Trends and Global Forecasts, till 2035" report has been added to ...

Atsena Therapeutics Reports New Preclinical Data Demonstrating Robust MYO7A Expression and Favorable Safety for ATSN-301, a Laterally Spreading Dual AAV Vector-based Gene ...

Dual vector and AAV.SPR technologies combine to drive supraphysiological levels of full-length MYO7A in non-human primate retina, reaching the ...